524 related articles for article (PubMed ID: 27777121)
1. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
[TBL] [Abstract][Full Text] [Related]
2. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
[TBL] [Abstract][Full Text] [Related]
4. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
[TBL] [Abstract][Full Text] [Related]
8. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
[TBL] [Abstract][Full Text] [Related]
9. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O
Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new lipid tear substitute in a mouse model of dry eye.
Scifo C; Barabino S; De Pasquale G; Blanco AR; Mazzone MG; Rolando M
Cornea; 2010 Jul; 29(7):802-6. PubMed ID: 20489574
[TBL] [Abstract][Full Text] [Related]
12. A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.
Gehlsen U; Braun T; Notara M; Krösser S; Steven P
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):767-775. PubMed ID: 28091781
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
[TBL] [Abstract][Full Text] [Related]
14. [Topical cyclosporine for the treatment of ocular surface changes in contact lens wearers].
Egorova GB; Mitichkina TS; Fedorov AA; Shamsudinova AR
Vestn Oftalmol; 2015; 131(1):36-42. PubMed ID: 25872385
[TBL] [Abstract][Full Text] [Related]
15. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
Leonardi A; Flamion B; Baudouin C
Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
Park CH; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Lee HK; Chung TY; Choi CY; Kim HS
Korean J Ophthalmol; 2019 Aug; 33(4):343-352. PubMed ID: 31389210
[TBL] [Abstract][Full Text] [Related]
17. Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium.
Ji YW; Kim HM; Ryu SY; Oh JW; Yeo A; Choi CY; Kim MJ; Song JS; Kim HS; Seo KY; Kim KP; Lee HK
Invest Ophthalmol Vis Sci; 2019 Dec; 60(15):5035-5044. PubMed ID: 31800960
[TBL] [Abstract][Full Text] [Related]
18. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
19. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
[TBL] [Abstract][Full Text] [Related]
20. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
